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Evidence relating to the impactof COVID-19 inpeoplewithdiabetes (PWD) is limited
but continuing toemerge.PWDappear tobeat increased riskofmoresevereCOVID-
19 infection, though evidence quantifying the risk is highly uncertain. The extent to
whichclinical anddemographic factorsmoderate this relationship isunclear, though
signals are emerging that link higher BMI and higher HbA1c to worse outcomes in
PWDwithCOVID-19.Aswell asposingdirect immediate risks toPWD,COVID-19also
risks contributing to worse diabetes outcomes due to disruptions caused by the
pandemic, including stress and changes to routine care, diet, and physical activity.
Countries have used various strategies to support PWDduring this pandemic. There
is a high potential for COVID-19 to exacerbate existing health disparities, and
research and practice guidelines need to take this into account. Evidence on the
management of long-termconditions during national emergencies suggests various
ways to mitigate the risks presented by these events.
People with diabetes (PWD) have been identified as being at increased risk of serious
illness from COVID-19. COVID-19 also presents substantial indirect risks to PWD
through disruptions in health care and lifestyle factors. Understanding these risks and
best ways tomitigate them in the short and longer term is key to facilitating informed
decision-making during and after the COVID-19 pandemic.
Evidence relating to COVID-19 and diabetes is limited but continuing to emerge.
In this Perspective, we summarize evidence identified through rapid reviews. We
consider direct and indirect risks posed to PWD by COVID-19 and management
considerations for PWD both with and without COVID-19 infection. Recognizing
limitations in evidence related to COVID-19, we also bring together leaders in diabetes
care from countries with high rates of COVID-19, highlighting experiences from the
most affected countries including Italy, France, China, the U.K., and the U.S.
DIABETES AND RISKS FROM COVID-19
COVID-19 Infection: Contracting the Disease
It is unclear if PWD are more likely to contract COVID-19. PWD are considered at
increased risk of infection generally, which has been extended to COVID-19 (1).
Community testing for COVID-19 remains limited; hence, data predominantly come
fromhospitalized cohorts. Systematic reviews primarily consisting of data fromChina
have estimated rates of 8% (95% CI 6–11%) (2), 7.87% (95% CI 6.57–9.28%) (3), and
9.7% (95% CI 6.9–12.5%) (4) of diabetes in people hospitalized with COVID-19. The
percentage hospitalization appears higher in the U.S., where from February 12 to 28
March2020, PWDaccounted for 10.9%of all COVID-19patients (similar to theproportion
of the U.S. population with diabetes), 24% of hospitalized cases (non–intensive care unit
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[ICU]), and 32% of ICU admissions (5). A
recent (preprint) U.K. study found uncom-
plicated diabetes to be the second most
common comorbidity (19%) in patients
hospitalized with COVID-19; complicated
diabetes is reported in a figure only but
prevalence looks to be approximately
6.5% (6).
COVID-19 Infection: Disease Severity
Though issues with study quality and
imprecision make it extremely difficult
to quantify, current data suggest that
COVID-19 is associated with worse out-
comes in PWD. Reports that aggregate
data frommultiple centers are summarized
inTable1.There isanotablepaucityofdata
on what moderates the relationship be-
tween diabetes and COVID-19 severity.
Increased age, being male, hyperten-
sion, and cardiovascular comorbidities
are associated with increased risks for
COVID-19 severity (7) and are likely to
be closely related to diabetes status. It is
plausible that BMI (8), ethnicity (9), type
of diabetes, diabetes control, and cer-
tain medications (10) all may also play a
role. In twocohort studies (Franceandthe
U.K., U.K. study preprint) in PWD hospital-
ized with COVID-19, higher BMI was pos-
itively associated with worse COVID-19
outcomes when compared with people
with BMI 25–29.9 kg/m2 (11,12). Data on
diabetes type and COVID-19 outcomes
are only beginning to emerge, but pre-
liminary (not yet peer reviewed) data
from England (see Table 1) suggest risks
may be higher in people with type 1
diabetes compared with type 2 (though
risk was increased in all PWD regardless
of type) (12). Data on glucose control and
COVID-19 outcomes are discussed below.
Association Between Blood Glucose
Control and COVID-19 Outcomes
There are limited data to date on the
association between blood glucose con-
trol and COVID-19 outcomes. A retro-
spective studyof 451peoplewithCOVID-19
with diabetes and/or hyperglycemia
from the U.S. reported that people with
uncontrolled hyperglycemia had longer
length of stay and higher mortality com-
pared with people without diabetes or
uncontrolledhyperglycemia (13).Another
retrospective study of people with type 2
diabetes from China reported that well-
controlled blood glucose correlated with
improved outcomes in infected patients
(14). Worse infection may predispose to
more difficulty managing blood glucose,
so the causal mechanism behind correla-
tions between glucose control and worse
COVID-19 outcomes is unclear.





participants Outcome measure Risk estimate
Systematic review and
meta-analysis (2)
Multiple 8 3,076 Risk of diabetes in severe patients
compared with nonsevere patients
OR 2.07, 95% CI 0.89–4.82
Systematic review and
meta-analysis (63)**
Multiple 9 2,103 Risk of diabetes in severe patients
compared with nonsevere patients
OR 2.67, 95% CI 1.91–3.7
Systematic review and
meta-analysis (4)
Multiple 6 1,527 Risk of diabetes in severe/ICU patients
compared with nonsevere (non-ICU)
patients
RR 2.21, 95% CI 0.88–5.57
Meta-analysis (64) China 12 2,018 Diabetes rate ratio among patients with
more severe versus those with less
severe infection





China n/a 72,314 Case fatality rate 7.3% in PWD (compared
with 2.3% overall)
U.S. Centers for Disease
Control and Prevention
report (5)
U.S. n/a 74,439 Not hospitalized PWD5 6% of all COVID-19 cases
Hospitalized, not in ICU PWD524%of all COVID-19 cases
Admitted to ICU PWD532%of all COVID-19 cases
Multicenter cohort study
(66)
China n/a 191 Risk of in-hospital death in PWD
compared with those without
(unadjusted)
OR 2.85, 95% CI 1.35–6.05
Retrospective review (67) China n/a 1,590 Likelihood of reaching composite end
point (admission to ICU, intensive
ventilation,ordeath) inPWDcompared
with those without (age- and smoking
status–adjusted)







Risk of in-hospital death in PWD
compared with those without (age-,
sex-, and comorbidities-adjusted)
HbA1c ,7.5% (58 mmol/mol);
HR 1.50, 95% CI 1.40–1.60.








Risk of in-hospital death in PWD
compared with those without
(adjusted for age, sex, deprivation,
ethnicity, geographical region)
Type 1 diabetes OR 3.50 (95%
CI 3.15–3.89); type 2 diabetes
OR 2.03 (95% CI 1.97–2.09)
HR, hazard ratio; OR, odds ratio; RR, risk ratio. *Definition of severe disease was often not clear; we report here what was reported in the primary
literature.Many of the systematic reviews include overlapping studies and have issueswith quality and reporting. **Preprintdmethods and data have
not been subject to peer review.
Two recent U.K. studies (both preprint)
reported that diabetes was independently
associated with a higher risk of death
that increased with higher HbA1c (12,15).
Compared with people without diabetes,
one study reported that PWDwith HbA1c
.7.5% (58 mmol/mol) had a higher
chance of in-hospital death than those
with HbA1c,7.5% (,7.5% HR 1.50 [95%
CI 1.40–1.60], $7.5% HR 2.36 [2.18–
2.56]) (15). In a separate analysis, PWD
with HbA1c .10% (86 mmol/mol) had a
higher risk of in-hospital death related to
COVID-19 than those with an HbA1c of
6.5–7% (48–53mmol/mol) (HbA1c.10%
compared with HbA1c 6.5–7% adjusted
HR 2.19 [95% CI 1.46–3.29] for type 1
diabetes, 1.62 [95% CI 1.48–1.79] for
type 2; in patients with type 2 diabetes,
a significant differencewas also detected
when comparing HbA1c values .7.5%
[59 mmol/mol] to the reference cate-
gory) (12). These data suggest that di-
abetes control preinfection has a role to
play in COVID-19outcomes. In contrast, a
French observational study in PWD hos-
pitalized with COVID-19 did not find an
association between long-term glucose
control and COVID-19 outcomes but had
a smaller sample (11).
Indirect Risks to PWD Posed by
COVID-19
Health care services, and in some cases
access to medication and supplies, have
been disrupted by COVID-19. Evidence
from other national emergencies shows
that such disruptions can lead to worse
diabetes outcomes during and after these
events (16–18). Diet and physical activity
aremainstaysofdiabetesself-management
and can reduce risk of worse outcomes in
PWDandthosewithcardiometabolicmulti-
morbidities (19). Though yet to be ad-
dressed by the COVID-19 literature, the
pandemic presents significant disruption
toboth: aU.S. surveyof PWD foundmore
than a third of respondents reported
their diet is now less healthy, and half
report exercising less (20). The current
pandemic and social isolation are likely to
increase rates of anxiety and depression,
whichmayalso lead topooradherence to




Reducing Risk from COVID-19
There is little evidence on how PWD can
reduce their risk during the COVID-19
pandemic beyond following general in-
fection control guidance within each
country. More frequent blood glucose
monitoring (in people who self-monitor)
has been suggested, though it is unclear
what evidence was used to make these
recommendations (1).
Considerations for Diabetes
Management in All PWD
Figure 1 summarizes specific considera-
tions for diabetes management during
national emergencies.
Self-management
There is little information on the effective-
ness of self-management/self-education
during the pandemic. A variety of online
services have been implemented but
have yet to be assessed (see EXPERIENCES
FROM COUNTRIES WITH HIGH RATES OF COVID-19).
Thewider literatureon care of long-term
conditions during national emergencies
suggests a role for educationalmaterials
(23). Evidence for interventions aiming
to optimize self-management in PWD
that are potentially feasible in disaster
contexts include mobile phone apps (24),
web- or computer-based interventions
(25), text messaging (26,27), and self-
monitoring of blood glucose (28,29).
The latter two show the most promise
based on the available literature. How-
ever, the interventions tested may not
bewidely available ormay require health
care resources to be set up. In addition,
choice of format should be tailored to
patient preferences, which will vary by
age and sociodemographic group (30).
Diabetes Services
Guidelines for routine diabetes care during
the COVID-19 pandemic vary by country.
Themes are summarized in Table 2. Studies
of remote consultations have generally
found positive results, though their gen-
eralizability to the current pandemicmay
be limited (31). Within diabetes, there is
little evidence to support or oppose re-
mote support (32,33).
MentalHealthandDiabetes-RelatedDistress
There are overarching concerns about
the impact of the COVID-19 pandemic on
mental health and well-being (34,35).
PWD are more prone to mental health
issues than the general population (36).
Adherence to treatment can worsen
when people are distressed or have de-
pression (21), as seen both during and
after disasters (37,38). We found no ev-
idence directly pertaining to management
of diabetes-related anxiety or distress
during this pandemic. In the general
literature, there is mixed evidence on
interventions to reduce diabetes-related
distress, and the vast majority of in-
terventions tested involve face-to-face
contactdan unsuitable format in the
current context (39).
Managing COVID-19 in PWD
Management of PWD with COVID-19
generally follows standard sick-day rules.
Considerations that may be specific to
COVID-19 are summarized below.
Medication
MostCOVID-19–relatedconsensus state-
ments recommend stopping metformin
and sodium–glucose cotransporter 2 in-
hibitors (SGLT2i) during acute illness and
following the sick-day rules. Dipeptidyl
peptidase 4 inhibitors (DPP-4i), glucagon-
like peptide 1 receptor agonists (GLP-
1RA),and insulinarethepreferredoptions
in particular for hospitalized patients
(see Fig. 2) (40,41). There has been some
discussion regarding use of ACE inhibitors
and angiotensin receptor blockers (ARBs)
being associatedwithworse outcomes in
COVID-19, particularly in PWD. However,
in view of data showing potential bene-
fits, the current recommendation is to
continue with these therapies (40).
A number of studies are currently
testing chloroquine/hydroxychloroquine
for prevention ormanagement of COVID-19.
Careful glucose monitoring will be re-
quired in PWD due to these drugs’ anti-
diabetic properties, with the potential
risk of hypoglycemia that is associated
with increased risk of cardiac arrhyth-
mia, cardiovascular events, and mor-
tality (42).
Management in Hospital
Guidance emphasizes the importance of
referring to local specialist diabetes teams
and of managing hyperglycemia (43). A
narrative review suggests insulin is the
preferred agent for control of hypergly-
cemia in this context (1). In the U.S., a
major early focus for hospital manage-
mentwas tomove inpatient care for PWD
to “virtual” formats where possible, to
reduce the need for personal protective
equipment. This included use of electronic
health records to interrogate data, tele-
phone communication between diabetes
care providers and inpatients and hospital
staff, expanded “diabetes self-management
protocols” allowing selected inpatients to
monitor their own glucose and self-administer
insulin with oversight and advice from
the virtual care team, and, in some
institutions, initiating inpatient continuous
glucose monitoring and/or flash systems.
Tominimize the need for ICU beds, several
institutions launched subcutaneous insulin
protocols for the treatment of diabetic
ketoacidosis on floors with adequate nurs-
ing staffing. Virtual diabetes care teams
focused on supporting transitions to lower
levels of care or outpatient settings.
EXPERIENCES FROM COUNTRIES
WITH HIGH RATES OF COVID-19
We summarize here experiences from
five countries that have had significant
COVID-19 outbreaks.
China
During the outbreak in China, many PWD
were unable to access health care pro-
viders (HCPs) or medical supplies due to
stay-at-home orders or quarantine. Hos-
pitals reduced the number of appoint-
ments drastically. Tomitigate the impact
of those changes on diabetes manage-
ment, several organizations issued guid-
ance to PWD on how to cope with the
situation (44,45). The guidance devel-
oped by the Chinese Geriatric Endocrine
Society mainly focused on prevention
and early discovery of hyperglycemic cri-
ses and management of medications and
provided detailed instructions on how to
get access to certified internet-based
medical services through smartphones
(45). If PWD urgently needed to see an
HCP in hospital, detailed guidance on
how to prepare for consultations before
leaving home and minimize exposure to
the virus were given en route and during
the hospital visit. Guidance was pro-
moted in the form of reading material
and lectures given by medical professio-
nals through internet-based public media
such as Baidu Health (an equivalent of
Google in China) and theWeChat mobile
app. An expert recommendation on in-
sulin treatment of hyperglycemia in patients
affected with COVID-19 was developed
(46).
France
On 12March, President Macron ordered
most people to stay at home, especially
“at-risk” groups, including PWD. Many
PWD were struck by the announcement
and were not expecting to be publicly
identified as such, without answers to
basic questions. On 18March, a group of
HCPs and researchers from the Federa-
tion of Diabetology launched a web app,
CoviDIAB, to provide PWDwith diabetes-
specific, scientifically based information
and to provide support. This free service
includes access to a frequently updated
media library and to live webinars with
nurses, physicians, and experts. Twice a
week, registrants also receive short ques-
tionnaires about COVID-19 symptoms and
tests for anxiety/depression. If indicated,
registrants automatically receive a no-
tice suggesting medical contact, and
phone calls may follow. At the time of
writing, tens of thousands of patients
were registered. Empathy was a driving
principle in design, and comments sug-
gest that the service helps people to
understand and self-manage their indi-
vidual risk and to limit disruption in
lifestyle and care. An evaluation will
indicate to what extent it reduces the
burden of disease. Recommendations
have been formulated by the French-
speaking Diabetes Society (Société
Francophone du Diabète) to promote
the intensification of glycemic control
by remote support by professionals
and frequent self-monitoring. How-
ever, extremely limited evidence was
available to guide both patients and
HCPs. In response, a group of physicians
and researchers from50Frenchhospitals
designed and launched a large register
to collect data on PWD hospitalized with
COVID-19 and their prognosis (COVID-19
and Diabetes Outcomes [CORONADO],
NCT04324736, ClinicalTrials.gov). Recruit-
ment has exceeded expectation; early
results are now available (11).
Italy
The first cases COVID-19 in Italy were
recorded early in February. Tragically,
Italy has suffered among the highest
numbers of deaths in the world (47). At
the time of this writing, the death rate in
Italy was estimated at 122.52 per 1,000
infections, i.e., a 10-fold higher rate than
in Germany (14.14 per 1,000 infections)
(48). This could be due to demographic
features of the Italian population, which
include a large proportion (23%) of peo-
ple aged $65 years (49). From 9 March,
social confinement rules were issued in-
clud-ing restricted access to outpatient
clinics. Access to diabetes clinics has
been limited to urgent cases, and remote
contacts via telephone or video telecon-
sultation have been officially approved
and reimbursed by the National Health
System. Prescriptions of glucose-lowering
agents requiring specialist approval
(DPP-4i, SGLT2i, GLP-1RA, and new basal
insulin analogs) were automatically re-
newed until the end ofMay. Special joint
recommendations have been promptly
issued by the Italian Society of Diabetes
(SID), the Association of Italian Diabetol-
ogists (AMD), the Italian Society of En-
docrinology (SIE), and the Italian Society
of Pediatric Endocrinology (SIEDP) (50).
The same organizations have opened a
Facebook page entitled “One hour with
Self-/remote
Figure 1—Considerations for diabetes management during national emergencies. T1D, type 1
diabetes.
AMD, SID, and SIEDP” allowing PWD and
their relatives to contact specialists (51).
A government web page providing sim-
ple and pragmatic recommendations has
been created focusing on disruptions to
physical activity and diet as a result of
social confinement (52). At the time of
writing, discussions were ongoing re-
garding restarting clinical activities
and how to organize post-COVID dia-
betes clinics.
U.K.
Over 90%of PWD in theU.K. aremanaged
in primary care, by enhanced diabetes-
skilled primary care physicians, nurses,
and health care assistants. These models
have shown to be effective in reducing
hospitalizations, outpatient attendance,
and admissions for diabetes-related
complications (53). In March, the govern-
ment issued guidance on social distanc-
ing and self-isolation (54). In England,
people considered especially clini-
cally vulnerable (including some but
not all PWD) were contacted by the
government with advice on shielding.
All people at high risk, including PWD,
were advised to only leave the house
for limited periods for essential shop-
ping and one form of exercise (55). The
Primary Care Diabetes Society and the
Association of British Clinical Diabetolo-
gists have issued guidance on managing
PWD in primary care (56). The national
charity Diabetes UK has been active in
giving advice to PWD through their web-
site and social media. Both primary and
secondary care are providing emergency
and routine follow-up using telephone or
video consultations including support for
mental well-being, though there are some
regional variations. Social media channels
have been set up where HCPs are sharing
experience in managing people in the
community and hospital and exchanging
new guidance. A number of self-manage-
menteducationprogramshavebeenmade
freely available. There are also discus-
sions regarding longer-term plans to
phase in face-to-face consultations for
routine chronic disease management.
U.S.
The lack of universal health coverage
poses additional challenges to PWD and
their care providers during the COVID-19
pandemic in the U.S. There has been an
almost wholesale switch to virtual care
for outpatient appointments, but there
aremany failings in this approach. Phone
visits provide a much lower rate of re-
imbursement than video visits, butmany
of the most vulnerable patients have
inadequate equipment or connectivity to
support video visits. Contacts with cer-
tified diabetes educators by phone or
video are not reimbursed. Additional
efforts have beenmade to communicate
with PWD at home to ensure that they
are safe. Laboratory and physical exam
monitoring of complications has virtu-
ally ceased for most patients as long
as they symptomatically remain well.
Table 2—Selection of guidance and recommendations relating to routine care in PWD during COVID-19 pandemic
Service Recommendations
Inpatient diabetes services c Inpatient diabetes services will need to continue and potentially increase capacity, with need for
team approach re: glycemic control and nutritional status, and consideration of “virtual visits” for
reviews (see MANAGEMENT IN HOSPITAL) (68).
Urgent/acute diabetes care (outpatient) c Face-to-face consultations should continue in the following circumstances: a new diagnosis of
T1D; urgent insulin start where symptomatic, HbA1c.10% (86 mmol/mol), or ketones detected;
teaching blood glucose monitoring for urgent reasons; or in cases where physical examination is
essential (e.g., foot ulcer, infection, some points in pregnancy) (69).
c Virtual (telephone, video, or e-mail) consultations should be used in the following circumstances:
follow-up of new T1D diagnoses; vulnerable patients (recent hospital admission, recurrent severe
hypoglycemia, HbA1c.11% [99mmol/mol]); intensive follow-up in high-risk situations; or where
risk of attending an appointment face-to-face is greater than the benefits (69).*
Routine diabetes care c Consider routine diabetes care delivered virtually in the context of broader long-term condition
management and prioritization, taking into account individual risk factors and clinical needs (68).
c The following should be deferred: routine appointments where diabetes is stable and well-
managed; face-to-face structured group education courses; flash glucose monitoring start
sessions; where the risk of attending an appointment is greater than the benefits; and where
deferring appointments will not compromise clinical care (69).
Foot services for PWD c Mayneedtocontinueat full capacitywithconsiderationofmovingsupport to remote formswhere
possible (68); many of these services are essential (70).
c Access to in-person support should continue for those with acute or limb-threatening problems
(70) or where physical examination is essential (69).
c All new referrals should ideally be reviewed within 24 h (70).
Pregnancy services for PWD c Mayneedtocontinueat full capacitywithconsiderationofmovingsupport to remote formswhere
possible (68).
c In-person support will be essential for physical examinations and/or teaching blood glucose
monitoring at some points in pregnancy (69).
Blood tests for PWD c Urgentbloodtestmonitoringshouldcontinue(e.g., decliningrenal function, raisedpotassium, low
sodium) (69).
Eye screening for PWD c This was not mentioned in the guidance reviewed but we understand in most affected countries
eye screening has been halted in view of high risk of transfer. Of note, evidence indicates that risk
stratifying is possible (71).
*PWD may be concerned about the need to visit hospital; they should be encouraged to contact their physician in case of any signs or symptoms
related to acute diabetes complications.
Many patients have lost insurance cov-
erage. Prescription fills for diabetesmed-
ications are down 10%; a survey of PWD
found one in six respondents needing
insulin experienced a problem. A similar
proportion reported issues with obtain-
ing test strips, and a quarter of respond-
ents reported issues with obtaining
pump or continuous glucose monitoring
supplies (20). Many pharmaceutical
companies have stepped in to increase
access to otherwise unaffordable med-
ications. In data available through the
end of March, relatively early in the U.S.
COVID-19 course, approximately 80% of
clinicians reported serious strain and
nearly two-thirds were uncertain whether
they would be able to keep their practices
open due to insufficient financial resources
and low volume of reimbursable work.
Overall visits (virtual and face-to-face) for
chronic asymptomatic care were down
;50% (57). As the future course of the
epidemic in theU.S. isuncertainandseems
likely to persist formanyweeks, the threat
to PWD is grave. The hope is that new
government initiatives and innovation on
the part of stakeholders will fill the






Evidence on the management of long-
term conditions during national emer-
gencies suggests variousways tomitigate
the risks presented by these events,
which predominantly fall under two phases:
planning and response (23). These strate-
gies are outlined in Table 3.
AFTER COVID-19
There is much uncertainty as to how the
COVID-19 pandemic will end and what
will be left in its wake. Disruptions that
arise due to national emergencies can
lead to increased HbA1c in those affected
up to 16 months later, with some evi-
dence that this is particularly the case for
people of lower socioeconomic status
and those treated with insulin (18,23). A
lack of access to routine health care is a
leading cause of morbidity and mortality
after disasters; stroke, acute myocardial
infarctions, and diabetes complica-
tions are all shown to increase after the
immediate threat has dissipated (26,58).
Services such as diabetes clinics may also
rethink their organization to minimize risk
of ongoing transmission.
CONCLUSIONS
The need for decisive action creates an
important tension when evidence is lim-
ited. An example here is the classification
of PWD as being at increased risk from
COVID-19 and therefore subject to in-
creased preventive measures. Though
risk is clearly increased, quantification is
scant. There is little to no evidence on
potentially moderating factors, despite
the fact that these data are routinely
collected in data sets used for existing
analyses; the results presented are often
unadjusted and use single disease cate-
gories, ignoring potential differences be-
tween type 1 and type 2 diabetes and
multimorbidities, which are associated
with worse outcomes (59).
In the face of a limited evidence base
relating directly to COVID-19, decisions
Figure 2—Possible flowchart for management of people hospitalized with diabetes and COVID-19, adapted with permission from Ceriello et al. (49).
ACEi, ACE inhibitors; AGIs,a-glucosidase inhibitors; BNP, brain natriuretic peptide; CAD, coronary artery disease; CGM, continuous glucosemonitoring;
CK, creatine kinase; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate (mL/min/ 1.73m2);MI, myocardial
infarction; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; OADs; oral antidiabetes drugs; PAD, peripheral arterial disease; RF, risk
factor; SUs, sulfonylureas; TIA, transient ischemic attack.
can be informed by international expe-
riences to date and, to someextent, from
the literature as it relates to other na-
tional emergencies. This latter source of
evidence shows the toll of disruptions to
diabetes care is often most pronounced
after the acute phase of the emergency
or disaster has passed. In some cases, the
excess morbidity and mortality in the
aftermath of national emergencies is
higher than the toll during the emer-
gency itself. History issues a stark warn-
ing here when considering the balance
between diverting resources toward the
acute COVID-19 crisis and maintaining
routine care for people living with long-
term conditions.
Finally, in reviewing what has been
written on the topic of diabetes and
COVID-19, we have been struck by two
noticeable absences. The first is the
absence of literature on wider contextual
factors. PWD are likely to be impacted by
COVID-19 just asmuchoutside thehealth
care setting as within it, with particular
concerns relating to disruptions to diet
and physical activity, increased stress,
and burdens on mental health and
well-being, yet the literature to date fo-
cuses almost exclusively on clinicalmanage-
ment. The other unspoken issue in the
literature we reviewed is that of inequality.
COVID-19 is not an equal-opportunity dis-
ease. The burden will disproportionally be
borne by people from less-advantaged
groups (60). Emerging data also suggest
that COVID-19 may pose more of a risk
to nonwhite ethnic groups (9). Diabetes
discriminates in similar ways, and the
intersection of diabetes and COVID-19
creates a maelstrom in which existing
health disparities risk exacerbation with
profound and long-lasting consequences.
COVID-19 holds a mirror to our health care
systems and care of PWD; may we do all
we can now to make that reflection favor-
able in hindsight.
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